Endoluminal Gastric Remodeling Technologies: Scientific Review and Clinical Perspectives

Abstract

Endoluminal gastric remodeling technologies represent a paradigm shift in the management of obesity and related metabolic disorders. These minimally invasive techniques, primarily executed via endoscopy, offer therapeutic alternatives to traditional bariatric surgery by achieving gastric volume reduction, altering gastric motility, and inducing neurohormonal changes to promote satiety and weight loss. Recent years have witnessed significant advancements in device design, procedural safety, and clinical outcomes, positioning endoluminal interventions as integral elements in contemporary obesity care. This review synthesizes recent evidence on the epidemiology, mechanisms, clinical presentation, diagnostic workup, management strategies, and guideline recommendations for endoluminal gastric remodeling, providing actionable insights for healthcare professionals involved in metabolic and bariatric therapy.

Introduction

Obesity is a global health crisis, with escalating prevalence and significant impact on morbidity, mortality, and healthcare costs. Traditional management has relied on lifestyle modification, pharmacotherapy, and bariatric surgery; however, the latter is associated with perioperative risk and limited accessibility. In response, endoluminal gastric remodeling technologies have emerged as viable, less invasive alternatives, bridging the therapeutic gap between medical and surgical interventions. These endoscopic procedures, leveraging intraluminal suturing, plication, and device-based mechanisms, facilitate weight reduction and metabolic improvement with favorable safety profiles. This article delves into the rationale, clinical applications, and procedural nuances of these innovative technologies, emphasizing their role in modern obesity management.

Epidemiology / Disease Burden

Obesity affects over 650 million adults worldwide and is associated with a spectrum of comorbidities including type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease, and certain malignancies. The World Health Organization underscores the urgent need for scalable, effective interventions. Despite the proven efficacy of bariatric surgery, less than 2% of eligible patients undergo these procedures due to access barriers, fear of complications, and patient preference. This treatment gap underscores the demand for minimally invasive modalities such as endoluminal gastric remodeling, which can potentially reach broader patient populations and mitigate the rising burden of obesity-related disease.

Pathophysiology

Endoluminal gastric remodeling capitalizes on fundamental principles of gastric physiology. Procedures such as endoscopic sleeve gastroplasty (ESG) and primary obesity surgery endolumenal (POSE) reduce gastric volume through transmural suturing or plication, limiting caloric intake and enhancing satiety. In addition to mechanical restriction, these interventions modulate gastric emptying and influence neurohormonal pathways, including ghrelin, GLP-1, and peptide YY, contributing to appetite suppression and improved glycemic control. Mechanism-based studies demonstrate that remodeling the gastric architecture alters fundal compliance and antral motility, reinforcing the multifactorial effects of these technologies on energy balance.

Risk Factors

Patient selection is critical to optimizing outcomes with endoluminal gastric remodeling. Ideal candidates typically exhibit class I or II obesity (BMI 30–40 kg/m²) with or without obesity-related comorbidities. Risk factors for procedural complications include previous gastric surgery, significant hiatal hernia, coagulopathy, and severe cardiopulmonary disease. Careful pre-procedural evaluation, including upper endoscopy and cross-sectional imaging, is essential to exclude anatomical contraindications and tailor the intervention to the patient’s risk profile. Understanding patient-specific factors, including age, metabolic status, and psychosocial readiness, further guides appropriate candidacy and post-procedural support.

Clinical Features

Patients presenting for endoluminal gastric remodeling often exhibit longstanding obesity refractory to lifestyle and pharmacologic measures. Common clinical features include elevated BMI, metabolic syndrome components (hypertension, dyslipidemia, insulin resistance), and obesity-related comorbidities. Assessment should encompass a comprehensive medical history, nutritional evaluation, and identification of weight-related complications. Informed consent must address procedural expectations, potential risks, and the importance of multidisciplinary follow-up to ensure sustained weight loss and comorbidity improvement.

Diagnosis

Diagnostic workup prior to endoluminal gastric remodeling involves a detailed evaluation of obesity phenotype, comorbidity burden, and gastrointestinal anatomy. Baseline laboratory studies assess metabolic status, liver function, and nutritional parameters. Upper gastrointestinal endoscopy is performed to exclude contraindications such as active ulceration, malignancy, or severe reflux disease. In selected cases, imaging studies such as abdominal ultrasound or CT scan may be warranted to delineate anatomy and exclude hepatic or pancreatic pathology. Standardized assessment tools, including quality of life indices and eating behavior questionnaires, provide baseline benchmarks for assessing procedural efficacy.

Treatment & Management

Endoluminal gastric remodeling encompasses a suite of procedures, most notably ESG and POSE. ESG utilizes a full-thickness endoscopic suturing device to create a tubular gastric sleeve, while POSE employs plication anchors to reduce gastric volume at the fundus and distal body. These procedures are typically performed under general anesthesia with low perioperative morbidity. Post-procedural management involves staged dietary advancement, nutritional supplementation, and structured behavioral support. Clinical trials demonstrate mean excess weight loss of 15–20% at 12–24 months, with concurrent improvements in glycemic control, blood pressure, and lipid profiles. Long-term success hinges on comprehensive, multidisciplinary follow-up and patient engagement in lifestyle modification.

Recent Advances / Emerging Therapies

Technological innovation continues to expand the therapeutic landscape of endoluminal gastric remodeling. Next-generation devices offer improved suture durability, enhanced procedural efficiency, and real-time imaging integration. Combination therapies, including endoscopic gastric remodeling plus pharmacotherapy (e.g., GLP-1 agonists), show promise for synergistic weight loss and metabolic benefit. Novel approaches targeting gastric electrical modulation and intragastric balloon technology further diversify treatment options. Ongoing clinical trials are evaluating long-term efficacy, durability of weight loss, and impact on obesity-related comorbidities, informing future practice and device refinement.

Guideline Recommendations

Professional societies, including the American Society for Gastrointestinal Endoscopy (ASGE) and the American Society for Metabolic and Bariatric Surgery (ASMBS), endorse endoluminal gastric remodeling as a safe and effective intervention for select patients with obesity who are not candidates for, or decline, surgical options. Guidelines emphasize the importance of multidisciplinary evaluation, structured post-procedure care, and ongoing surveillance for weight recurrence and metabolic complications. Patient education, shared decision-making, and personalized therapy selection remain central tenets of guideline-directed care.

Conclusion

Endoluminal gastric remodeling technologies have transformed the landscape of obesity management, offering evidence-based, minimally invasive alternatives to conventional bariatric surgery. With robust clinical efficacy, favorable safety profiles, and expanding indications, these interventions are poised to play a pivotal role in curbing the global obesity epidemic. Continued research, technological innovation, and adherence to guideline-based practice will further optimize patient outcomes and broaden the therapeutic reach of these transformative technologies.